Skip to content

Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors

Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation (VBS-CSI) With Proton Therapy in Pediatric Tumors: A Single-Center Prospective Observational Cohort Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07589361
Acronym
VBS-CSI-PT-PED
Enrollment
38
Registered
2026-05-15
Start date
2026-04-30
Completion date
2033-12-31
Last updated
2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atypical Teratoid/Rhabdoid Tumor (AT/RT), Ependymoma, Germinoma, Medulloblastoma, Pediatric Central Nervous System Tumors

Brief summary

his is a single-center, prospective observational study in children and adolescents with central nervous system tumors who need whole-brain and whole-spine radiation therapy (craniospinal irradiation, CSI). The study uses proton therapy with a special vertebral body-sparing (VBS) technique to protect the front and center of the vertebrae, which helps preserve bone marrow function and growth. The main goals are to find safe dose limits for the vertebrae and check how often severe side effects occur. The study will also look at bone marrow preservation, spinal deformity, tumor control, survival, chemotherapy completion, neurocognitive function, quality of life, and growth and development for up to 5 years after treatment.

Interventions

RADIATIONVertebral Body-Sparing Craniospinal Proton Irradiation

Vertebral body-sparing craniospinal irradiation (VBS-CSI) using intensity-modulated proton therapy (IMPT, pencil-beam scanning). The treatment actively restricts radiation dose to the anterior and central regions of thoracolumbar vertebral bodies to preserve active bone marrow and spinal growth potential, while ensuring adequate target coverage for the whole brain and spinal cord. Two dose levels are applied: 23.4 Gy(RBE)/13 fractions or 24 Gy(RBE)/15 fractions and 36 Gy(RBE)/20 fractions.

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
4 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* The patient's legal guardian voluntarily signs the written informed consent form. * Age at diagnosis \> 3 years and ≤ 18 years. * Histopathologically confirmed diagnosis of a central nervous system (CNS) tumor. * Indication for craniospinal irradiation (CSI) confirmed by multidisciplinary team (MDT) discussion. * Karnofsky Performance Score (KPS) ≥ 80. * For postoperative patients, complete healing of the surgical incision with no evidence of wound infection or other complications. * For women of childbearing potential, effective contraception must be used for at least one month prior to screening, and they must commit to continued contraception throughout the study period and for the required time after study completion.

Exclusion criteria

* Previous receipt of any form of spinal radiotherapy. * Previous major spinal surgery for any reason. * Presence of clinically significant and confirmed spinal deformity at enrollment (e.g., Cobb angle \> 10° measured by MRI or X-ray). * Presence of medical contraindications to proton radiotherapy. * Presence of any severe, uncontrolled systemic disease (e.g., active infection, severe cardiac, hepatic, renal, or respiratory insufficiency) that, in the investigator's judgment, makes the subject unsuitable for treatment under this protocol. * Female patients who are pregnant or breastfeeding. * Presence of any severe cognitive or psychiatric disorder that prevents understanding of or cooperation with study assessments.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of ≥ Grade 3 acute adverse eventsUp to 3 months after completion of radiotherapyTo evaluate the incidence of treatment-related acute adverse events of grade 3 or higher, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).

Secondary

MeasureTime frameDescription
Active Bone Marrow Preservation RateBaseline, 3, 6, 12, 24, 36, 48, 60 monthsThe proportion of active bone marrow in the vertebral body is calculated by dividing the width of the low-signal area by the total diameter of the vertebral body, which allows a relatively quantitative assessment of the active bone marrow preservation rate.
Incidence of spinal deformityBaseline and at 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months after treatment completionEvaluation is performed using whole-neuraxis MRI or whole-spine anteroposterior and lateral X-ray films. Spinal scoliosis is quantitatively assessed using the Cobb angle measurement method by a radiologist who is blinded to the patient's specific treatment information. The degree of kyphosis is evaluated by assessing the presence of thoracic kyphosis. Additionally, vertebral body change characteristics of the thoracolumbar spine are measured, including the posterior-to-anterior ratio (PARs) of the vertebral body-defined as the ratio of the posterior vertebral body height to the anterior vertebral body height-as well as intervertebral disc height.

Contacts

CONTACTJiayi Chen
cjy11756@rjh.com.cn+86 021 64370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 16, 2026